These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 16104903

  • 1. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
    Stephan C, Jung K, Soosaipillai A, Yousef GM, Cammann H, Meyer H, Xu C, Diamandis EP.
    BJU Int; 2005 Sep; 96(4):521-7. PubMed ID: 16104903
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lümmen G, Wernli M, Wiefelspütz J, Graber SF, Goepel M, Huber A, Tscholl R.
    Cancer; 1998 Dec 15; 83(12):2540-7. PubMed ID: 9874461
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H, Sokoll LJ, Partin AW.
    J Urol; 2005 Mar 15; 173(3):752-6. PubMed ID: 15711262
    [Abstract] [Full Text] [Related]

  • 6. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
    Steuber T, Niemela P, Haese A, Pettersson K, Erbersdobler A, Felix Chun KH, Graefen M, Kattan MW, Huland H, Lilja H.
    Prostate; 2005 Apr 01; 63(1):13-8. PubMed ID: 15378521
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH, Roobol M, Jenster G, Schröder FH, Bangma CH.
    Eur Urol; 2009 Mar 01; 55(3):563-74. PubMed ID: 19058905
    [Abstract] [Full Text] [Related]

  • 10. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, Schnorr D, Loening SA, Jung K.
    Cancer; 2005 Sep 01; 104(5):993-1003. PubMed ID: 16007682
    [Abstract] [Full Text] [Related]

  • 11. The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer.
    Bangma CH, Wildhagen MF, Yurdakul G, Schröder FH, Blijenberg BG.
    BJU Int; 2004 Apr 01; 93(6):720-4. PubMed ID: 15049979
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics.
    Stephan C, Cammann H, Meyer HA, Müller C, Deger S, Lein M, Jung K.
    BJU Int; 2008 Sep 01; 102(7):799-805. PubMed ID: 18522632
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
    Björk T, Schalken J, Wittjes W, Ljungberg B, Lilja H.
    Prostate; 2001 Apr 01; 47(1):14-20. PubMed ID: 11304725
    [Abstract] [Full Text] [Related]

  • 17. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
    Lein M, Jung K, Hammerer P, Graefen M, Semjonow A, Stieber P, Ossendorf M, Luboldt HJ, Brux B, Stephan C, Schnorr D, Loening SA.
    Prostate; 2001 May 01; 47(2):77-84. PubMed ID: 11340629
    [Abstract] [Full Text] [Related]

  • 18. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
    Haese A, Graefen M, Steuber T, Becker C, Pettersson K, Piironen T, Noldus J, Huland H, Lilja H.
    Prostate; 2001 Oct 01; 49(2):101-9. PubMed ID: 11582588
    [Abstract] [Full Text] [Related]

  • 19. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
    Lein M, Jung K, Elgeti U, Brux B, Sinha P, Schnorr D, Loening SA.
    Anticancer Res; 2000 Oct 01; 20(6D):4997-5001. PubMed ID: 11326657
    [Abstract] [Full Text] [Related]

  • 20. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
    Parsons JK, Brawer MK, Cheli CD, Partin AW, Djavan R.
    BJU Int; 2004 Jul 01; 94(1):47-50. PubMed ID: 15217429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.